While optimization of CAR design, manufacturing protocols, and strategies to overcome exhaustion remain areas for refinement, the MR1-centric biology and innatelike cytotoxic breadth of MAIT cells position them as a compelling candidate to counter tumor antigen escape in nextgeneration immunotherapeutic platforms. Here, MR1 is linked to neoplasm.